<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04477785</url>
  </required_header>
  <id_info>
    <org_study_id>PPMI-002</org_study_id>
    <nct_id>NCT04477785</nct_id>
  </id_info>
  <brief_title>PPMI 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort</brief_title>
  <acronym>PPMI</acronym>
  <official_title>The Parkinson's Progression Markers Initiative (PPMI) 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael J. Fox Foundation for Parkinson's Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute for Neurodegenerative Disorders</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Michael J. Fox Foundation for Parkinson's Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational,&#xD;
      multi-center natural history study to assess progression of clinical features, digital&#xD;
      outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression&#xD;
      in study participants with manifest PD, prodromal PD, and healthy controls&#xD;
&#xD;
      The overall goal of PPMI 2.0 is to identify markers of disease progression for use in&#xD;
      clinical trials of therapies to reduce progression of PD disability.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PPMI 2.0 is a broad program, expanding the goals of the original PPMI study (NCT01141023),&#xD;
      that includes this PPMI 2.0 Clinical protocol, as well as the PPMI 2.0 Remote, PPMI 2.0&#xD;
      Digital Applications and PPMI 2.0 Online protocols. All participants in PPMI 2.0 will be&#xD;
      asked to be enrolled in all PPMI 2.0 protocols, but depending on their method of recruitment,&#xD;
      participants may be enrolled sequentially in varying order, as appropriate. PPMI 2.0&#xD;
      participants may also be asked to participate in additional PPMI 2.0 companion studies (as&#xD;
      they are developed), which may only involve a subset of PPMI 2.0 participants based on their&#xD;
      cohort designation and/or site location.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 2033</completion_date>
  <primary_completion_date type="Anticipated">December 2033</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Establish standardized protocols for acquisition, transfer &amp; analysis of clinical, digital, imaging, biologic and genetic data that can be used in the PD research community.</measure>
    <time_frame>Baseline to 156 months</time_frame>
    <description>This protocol will build on the existing PPMI infrastructure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comprehensive and uniformly acquired dataset</measure>
    <time_frame>Baseline to 156 months</time_frame>
    <description>Develop a comprehensive and uniformly acquired clinical, digital and imaging dataset and repository of biological and genetic samples that would be available to the PD research community to test hypotheses of the underlying molecular pathobiology of PD, enable modeling of PD progression to identify clinical and/or data driven PD progression sub-sets, and inform studies testing PD therapeutics (for examples, clinical trials targeting synuclein, LRRK2, GBA as well as other targets)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison between Rates of Change</measure>
    <time_frame>Study intervals ranging from 3 months to 156 months</time_frame>
    <description>Use clinical and biological data to estimate the mean rates of change and the variability around the mean of clinical, digital, imaging, biological and genetic outcomes in study participants with PD diagnosis (including patients with a LRRK2, GBA, SNCA or rare genetic mutations (such as Parkin or Pink1) and individuals with prodromal Parkinson disease (including individuals with RBD, olfactory loss, LRRK2, GBA, SNCA or rare genetic mutations (such as Parkin or Pink1) and/or other risk factors for PD with and without DAT deficit and in healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of measures of clinical, imaging and biomic outcomes in various subsets</measure>
    <time_frame>study intervals ranging from baseline to 156 months.</time_frame>
    <description>Confirm existing and identify novel clinical, digital, imaging, biologic and genetic PD progression markers to identify quantitative individual measures or combinations of measures that demonstrate optimum interval change in study participants with PD diagnosis (including patients with a LRRK2, GBA, SNCA or rare genetic mutations (such as Parkin or Pink1)) and individuals with prodromal Parkinson disease (including individuals with RBD, olfactory loss, a LRRK2, GBA, SNCA or rare genetic mutations (such as Parkin or Pink1) and/or other risk factors for PD with and without DAT deficit in comparison to healthy controls or in sub-sets of study participants with PD diagnosis or prodromal PD defined by baseline assessments, progression milestones and/or rate of clinical, digital, imaging, biologic and genetic change, or other measures.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Establish the probability of phenoconversion to PD</measure>
    <time_frame>study intervals ranging from baseline to 156 months.</time_frame>
    <description>Evaluate the probability of phenoconversion to PD for individuals with prodromal PD enrolled in the prodromal cohorts (including individuals with RBD, olfactory loss, a LRRK2, GBA, SNCA or rare genetic mutations (such as Parkin or Pink1) and/ or other risk factors for PD with and without DAT deficit).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">4500</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Clinical Observation</arm_group_label>
    <description>Up to 4500 participants will be followed clinically once identified, over the course of 5-8 years.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood will be obtained for the extraction of DNA to conduct sequencing and genomic analysis.&#xD;
      These maybe collected in a fasted state.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        In PPMI 2.0 Clinical up to 4,500 participants will be enrolled and followed longitudinally&#xD;
        from approximately 40-50 international clinical sites across a variety of cohorts,&#xD;
        including healthy controls, Parkinson disease, PD manifesting gene carriers, and Prodromal&#xD;
        (those at risk for developing PD).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Parkinson Disease (PD) Subjects:&#xD;
&#xD;
          -  Male or female age 30 years or older at Screening Visit.&#xD;
&#xD;
          -  A diagnosis of Parkinson disease for 2 years or less at Screening Visit.&#xD;
&#xD;
          -  Not expected to require PD medication with at least 6 months from Baseline.&#xD;
&#xD;
          -  Patients must have at least two of the following: resting tremor, bradykinesia,&#xD;
             rigidity (must have either resting tremor or bradykinesia); OR either asymmetric&#xD;
             resting tremor or asymmetric bradykinesia.&#xD;
&#xD;
          -  Hoehn and Yahr stage I or II at Baseline.&#xD;
&#xD;
          -  Individuals taking any of the following drugs: alpha methyldopa, methylphenidate,&#xD;
             amphetamine derivatives or modafinil, must be willing and medically able to hold the&#xD;
             medication for at least 5 half-lives before DaTscan imaging.&#xD;
&#xD;
          -  Confirmation that participant is eligible based on Screening DaTscan imaging.&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Woman may not be pregnant, lactating or planning pregnancy during the study.&#xD;
             ~Including a negative pregnancy test on day of Screening DaTscan imaging test prior to&#xD;
             injection of DaTscan.&#xD;
&#xD;
        Healthy Control (HC) Subjects:&#xD;
&#xD;
          -  Male or female age 30 years or older at Screening visit.&#xD;
&#xD;
          -  Individuals taking any of the following drugs: alpha methyldopa, methylphenidate,&#xD;
             amphetamine derivatives or modafinil, must be willing and medically able to hold the&#xD;
             medication for at least 5 half-lives before DaTscan imaging.&#xD;
&#xD;
          -  Confirmation that participant is eligible based on Screening DaTscan imaging.&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Women may not be pregnant, lactating or planning pregnancy during the study. ~&#xD;
             Includes a negative pregnancy test on day of Screening DaTscan imaging test prior to&#xD;
             injection of DaTscan™.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Parkinson Disease (PD) Subjects:&#xD;
&#xD;
          -  Currently taking levodopa, dopamine agonists, MAO-B inhibitors (e.g., selegiline,&#xD;
             rasagiline), amantadine or other PD medication.&#xD;
&#xD;
          -  Has taken levodopa, dopamine agonists, MAO-B inhibitors or amantadine within 60 days&#xD;
             of Baseline.&#xD;
&#xD;
          -  Has taken levodopa or dopamine agonists prior to Baseline for more than a total of 90&#xD;
             days.&#xD;
&#xD;
          -  Atypical PD syndromes due to either drugs (e.g., metoclopramide, flunarizine,&#xD;
             neuroleptics) or metabolic disorders (e.g., Wilson's disease), encephalitis, or&#xD;
             degenerative diseases (e.g., progressive supranuclear palsy)&#xD;
&#xD;
          -  A clinical diagnosis of dementia as determined by the investigator.&#xD;
&#xD;
          -  Previously obtained MRI scan with evidence of clinically significant neurological&#xD;
             disorder (in the opinion of the Investigator)&#xD;
&#xD;
          -  Received any of the following drugs: dopamine receptor blockers (neuroleptics),&#xD;
             metoclopramide and reserpine within 6 months of Screening visit.&#xD;
&#xD;
          -  Current treatment with anticoagulants (e.g. coumadin, heparin, oral thrombin&#xD;
             inhibitors) that might preclude safe completion of lumbar puncture.&#xD;
&#xD;
          -  Condition that precludes the safe performance of routine lumbar puncture, such as&#xD;
             prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant&#xD;
             coagulopathy or thrombocytopenia.&#xD;
&#xD;
          -  Any other medical or psychiatric condition or lab abnormality, which in the opinion of&#xD;
             the investigator might preclude participation.&#xD;
&#xD;
        Healthy Control (HC) Subjects:&#xD;
&#xD;
          -  Current or active clinically significant neurological disorder (in the opinion of the&#xD;
             Investigator).&#xD;
&#xD;
          -  First degree relative with PD (parent, sibling, child).&#xD;
&#xD;
          -  Previously obtained MRI scan with evidence of clinically significant neurological&#xD;
             disorder (in the opinion of the Investigator)&#xD;
&#xD;
          -  Received any of the follow drugs: dopamine receptor blockers (neuroleptics),&#xD;
             metoclopramide and reserpine within 6 months of Screening visit.&#xD;
&#xD;
          -  Current treatment with anticoagulants (e.g., coumadin, heparin, oral thrombin&#xD;
             inhibitors) that might preclude safe completion of the lumbar puncture.&#xD;
&#xD;
          -  Condition that precludes the safe performance of routine lumbar puncture, such as&#xD;
             prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant&#xD;
             coagulopathy or thrombocytopenia.&#xD;
&#xD;
          -  Any other medical or psychiatric condition or lab abnormality, which in the opinion of&#xD;
             the investigator might preclude participation.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        (PD-LRRK2 or GBA) Participants:&#xD;
&#xD;
          -  Male or female age 30 years or older at Screening visit.&#xD;
&#xD;
          -  A diagnosis of Parkinson disease for 2 years or less at Screening Visit.&#xD;
&#xD;
          -  Patients must have a least two of the following: resting tremor, bradykinesia,&#xD;
             rigidity (must have either resting tremor or bradykinesia); OR either asymmetric&#xD;
             resting tremor or asymmetric bradykinesia.&#xD;
&#xD;
          -  Hoehn and Yahr stage I or II at Baseline.&#xD;
&#xD;
          -  Confirmation of causative LRRK2 or GBA (willingness to undergo genetic testing as part&#xD;
             of genetic screening and be informed of genetic testing results, or documentation of&#xD;
             prior genetic testing results).&#xD;
&#xD;
          -  Individuals taking any of the following drugs: alpha methyldopa, methylphenidate,&#xD;
             amphetamine derivatives or modafinil, must be willing and medically able to hold the&#xD;
             medication for at least 5 half-lives before DaTscan imaging.&#xD;
&#xD;
          -  Confirmation that participant is eligible based on Screening DaTscan imaging.&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Woman may not be pregnant, lactating or planning pregnancy during the study.&#xD;
             ~Including a negative pregnancy test on day of Screening DaTscan imaging test prior to&#xD;
             injection of DaTscan™.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        PD-LRRK2 or GBA&#xD;
&#xD;
          -  Received any of the following drugs: dopamine receptor blockers (neuroleptics),&#xD;
             metoclopramide and reserpine within 6 months of Screening visit.&#xD;
&#xD;
          -  Current treatment with anticoagulants (e.g., coumadin, heparin) that might preclude&#xD;
             safe completion of the lumbar puncture&#xD;
&#xD;
          -  Condition that precludes the safe performance of routine lumbar puncture, such as&#xD;
             prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant&#xD;
             coagulopathy or thrombocytopenia.&#xD;
&#xD;
          -  Any other medical or psychiatric condition or lab abnormality, which in the opinion of&#xD;
             the investigator might preclude participation.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        PD-SNCA or rate genetic mutation (such as Parkin or Pink 1))&#xD;
&#xD;
          -  Male or female age 30 years or older at Screening Visit.&#xD;
&#xD;
          -  Parkinson disease diagnosis at Screening Visit.&#xD;
&#xD;
          -  Patients must have at least two of the following: resting tremor, bradykinesia,&#xD;
             rigidity (must have either resting tremor or bradykinesia); OR either asymmetric&#xD;
             resting tremor or asymmetric bradykinesia.&#xD;
&#xD;
          -  Hoehn and Yahr stage I, II or III at Baseline.&#xD;
&#xD;
          -  Confirmation of causative SNCA or rare genetic mutation (such as Parkin or Pink 1)&#xD;
             (willingness to undergo genetic testing as part of genetic screening and be informed&#xD;
             of genetic testing results, or documentation of prior genetic testing results).&#xD;
&#xD;
          -  Individuals taking any of the following drugs: alpha methyldopa, methylphenidate,&#xD;
             amphetamine derivatives or modafinil, must be willing and medically able to hold the&#xD;
             medication for at least 5 half-lives before DaTscan imaging.&#xD;
&#xD;
          -  Confirmation that participant is eligible based on Screening DaTscan imaging.&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Woman may not be pregnant, lactating or planning pregnancy during the study.&#xD;
             ~Including a negative pregnancy test on day of Screening DaTscan imaging test prior to&#xD;
             injection DaTscan™.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        PD-SNCA or rate genetic mutation (such as Parkin or Pink 1))&#xD;
&#xD;
          -  Received any of the following drugs: dopamine receptor blockers (neuroleptics),&#xD;
             metoclopramide and reserpine within 6 months of Screening visit.&#xD;
&#xD;
          -  Current treatment with anticoagulants (e.g., coumadin, heparin) that might preclude&#xD;
             safe completion of the lumbar puncture&#xD;
&#xD;
          -  Condition that precludes the safe performance of routine lumbar puncture, such as&#xD;
             prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant&#xD;
             coagulopathy or thrombocytopenia.&#xD;
&#xD;
          -  Any other medical or psychiatric condition or lab abnormality, which in the opinion of&#xD;
             the investigator might preclude participation.&#xD;
&#xD;
        Prodromal Subjects:&#xD;
&#xD;
        Inclusion Criteria For Screening:&#xD;
&#xD;
          -  Enrolled in PPMI 2.0 Remote and based on risk criteria, or olfaction, and/or other&#xD;
             assessments in the PPMI 2.0 Online protocol are eligible for PPMI 2.0 Clinical.&#xD;
&#xD;
          -  Male or female age 60 years or older (except age 30 years or older for SNCA, or rate&#xD;
             genetic mutations (such as Parkin or Pink1) participants).&#xD;
&#xD;
          -  Individuals taking any of the following drugs: alpha methyldopa, methylphenidate,&#xD;
             amphetamine derivatives or modafinil, must be willing and medically able to hold the&#xD;
             medication for at least 5 half-lives before DaTscan imaging.&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Woman may not be pregnant, lactating or planning pregnancy during the study.&#xD;
             ~Including a negative pregnancy test on day of Screening DaTscan imaging test prior to&#xD;
             injection of DaTscan™.&#xD;
&#xD;
        Exclusion Criteria : Prodromal&#xD;
&#xD;
          -  Clinical diagnosis of PD, other parkinsonism, or dementia&#xD;
&#xD;
          -  Received any of the following drugs: dopamine receptor blockers (neuroleptics),&#xD;
             metoclopramide and reserpine within 6 months of Screening visit.&#xD;
&#xD;
          -  Current treatment with anticoagulants (e.g. coumadin, heparin) that might preclude&#xD;
             safe completion of the lumbar puncture.&#xD;
&#xD;
          -  Condition that precludes the safe performance of routine lumbar puncture, such as&#xD;
             prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant&#xD;
             coagulopathy or thrombocytopenia.&#xD;
&#xD;
          -  Any other medical or psychiatric condition or lab abnormality, which in the opinion of&#xD;
             the investigator might preclude participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth L Marek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Neurodegenerative Disorders</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Caroline Tanner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cari Rainville, BS</last_name>
    <phone>877-525-7764</phone>
    <email>crainville@indd.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PPMI Call Center</last_name>
      <phone>877-525-7764</phone>
    </contact>
    <investigator>
      <last_name>Victor Sung, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amy Amara</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PPMI Call Center</last_name>
      <phone>877-525-7764</phone>
    </contact>
    <investigator>
      <last_name>Holly Shill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Foundation for Medical Education and Research</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PPMI Call Center</last_name>
      <phone>877-525-7764</phone>
    </contact>
    <investigator>
      <last_name>Charles Adler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner Research Institute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PPMI Call Center</last_name>
      <phone>877-525-7764</phone>
    </contact>
    <investigator>
      <last_name>Sara Dhanani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Shprecher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0948</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PPMI Call Center</last_name>
      <phone>877-525-7764</phone>
    </contact>
    <investigator>
      <last_name>Douglas Galasko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keck School of Medicine of USC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PPMI Call Center</last_name>
      <phone>877-525-7764</phone>
    </contact>
    <investigator>
      <last_name>Mark Lew</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PPMI Call Center</last_name>
      <phone>877-525-7764</phone>
    </contact>
    <investigator>
      <last_name>Caroline Tanner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PPMI Call Center</last_name>
      <phone>877-525-7764</phone>
    </contact>
    <investigator>
      <last_name>Maureen Leehey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute For Neurodegenerative Disorders</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PPMI Call Center</last_name>
      <phone>877-525-7764</phone>
    </contact>
    <investigator>
      <last_name>David Russell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease&amp; Movement Disorder Center of Boca Raton</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PPMI Call Center</last_name>
      <phone>877-525-7764</phone>
    </contact>
    <investigator>
      <last_name>Nikolaus McFarland</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PPMI Call Center</last_name>
      <phone>877-525-7764</phone>
    </contact>
    <investigator>
      <last_name>Stewart A Factor, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PPMI Call Center</last_name>
      <phone>877-525-7764</phone>
    </contact>
    <investigator>
      <last_name>Tanya Simuni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PPMI Call Center</last_name>
      <phone>877-525-7764</phone>
    </contact>
    <investigator>
      <last_name>Rajesh Pahwa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PPMI Call Center</last_name>
      <phone>877-525-7764</phone>
    </contact>
    <investigator>
      <last_name>Emile Moukheiber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PPMI Call Center</last_name>
      <phone>877-525-7764</phone>
    </contact>
    <investigator>
      <last_name>Marie H. Saint-Hilaire, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02446</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PPMI Call Center</last_name>
      <phone>877-525-7764</phone>
    </contact>
    <investigator>
      <last_name>Aleksandar Videnovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PPMI Call Center</last_name>
      <phone>877-525-7764</phone>
    </contact>
    <investigator>
      <last_name>Kelvin Chou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Lou Ruvo Center for Brain Health</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PPMI Call Center</last_name>
      <phone>877-525-7764</phone>
    </contact>
    <investigator>
      <last_name>Zoltan Mari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PPMI Call Center</last_name>
      <phone>877-525-7764</phone>
    </contact>
    <investigator>
      <last_name>Susan Bressman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PPMI Call Center</last_name>
      <phone>877-525-7764</phone>
    </contact>
    <investigator>
      <last_name>Un Kang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giulietta Riboldi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PPMI Call Center</last_name>
      <phone>877-525-7764</phone>
    </contact>
    <investigator>
      <last_name>Ruth Schneider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati/Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PPMI Call Center</last_name>
      <phone>877-525-7764</phone>
    </contact>
    <investigator>
      <last_name>Alberto Espay, MD, MSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PPMI Call Center</last_name>
      <phone>877-525-7764</phone>
    </contact>
    <investigator>
      <last_name>Hubert H. Fernandez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp;Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PPMI Call Center</last_name>
      <phone>877-525-7764</phone>
    </contact>
    <investigator>
      <last_name>Penelope Hogarth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PPMI Call Center</last_name>
      <phone>877-525-7764</phone>
    </contact>
    <investigator>
      <last_name>Nabila Dahodwala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PPMI Call Center</last_name>
      <phone>877-525-7764</phone>
    </contact>
    <investigator>
      <last_name>Lana Chahine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PPMI Call Center</last_name>
      <phone>877-525-7764</phone>
    </contact>
    <investigator>
      <last_name>Arjun Tarakad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univ of Washington and VA Puget Sound Health Care System</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PPMI Call Center</last_name>
      <phone>877-525-7764</phone>
    </contact>
    <investigator>
      <last_name>Shu-Ching Hu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Innsbruck Medical University</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dora Valent, PhD</last_name>
      <email>dora.valent@tirol-kliniken.at</email>
    </contact>
    <investigator>
      <last_name>Werner Poewe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital - Civic Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PPMI Call Center</last_name>
      <phone>877-525-7764</phone>
    </contact>
    <investigator>
      <last_name>Tiago Mestre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PPMI Call Center</last_name>
      <phone>877-525-7764</phone>
    </contact>
    <investigator>
      <last_name>Connie Marras</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3A2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PPMI Call Center</last_name>
      <phone>877-525-7764</phone>
    </contact>
    <investigator>
      <last_name>Ron Postuma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephanie Carvalho</last_name>
      <phone>+33142165769</phone>
      <email>stephanie.carvalho@icm-institute.org</email>
    </contact>
    <investigator>
      <last_name>Jean-Christophe Corvol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paracelsus-Elena Klinik</name>
      <address>
        <city>Kassel</city>
        <zip>34128</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Willeke</last_name>
      <phone>49 561 6009 272</phone>
      <email>diana.willeke@pk-mx.de</email>
    </contact>
    <investigator>
      <last_name>Brit Mollenhauer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Luebeck</name>
      <address>
        <city>Luebeck</city>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norbert Bruggermann</last_name>
      <email>norbert.brueggemann@neuro.uni-luebeck.de</email>
    </contact>
    <investigator>
      <last_name>Christine Klein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ella Hilt</last_name>
      <phone>+49 7072 298621</phone>
      <email>ella.hilt@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Isabel Wurster, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathrin Brockmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Foundation for Biomedical Research of the Academy of Athens</name>
      <address>
        <city>Athens</city>
        <zip>11523</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christos Koros</last_name>
      <phone>00302107289405</phone>
      <email>chkoros@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Leonidas Stefanis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shira Paz, Bsc</last_name>
      <phone>+97236973014</phone>
      <email>shirapaz@tlvmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Nir Giladi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Salerno</name>
      <address>
        <city>Salerno</city>
        <zip>84131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Ainscough, BA</last_name>
      <phone>39 340 519 2659</phone>
      <email>ricercaparkinson@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Paolo Barone, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud University</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myrthe Burgler</last_name>
      <email>myrthe.burgler@radboudumc.nl</email>
    </contact>
    <investigator>
      <last_name>Baastian Bloem</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Grete Kristiansen</last_name>
      <phone>47072573528</phone>
      <email>anne.g.kristiansen@ntnu.no</email>
    </contact>
    <investigator>
      <last_name>Jan O. Aasly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Garrido, MD</last_name>
      <phone>34 932275785</phone>
      <email>agarridop@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Eduardo Tolosa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Jose Marti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Donostia</name>
      <address>
        <city>San Sebastian</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ioana Croitoru</last_name>
      <phone>+34 943 00 72 46</phone>
      <email>ioana.croitoru@biodonostia.org</email>
    </contact>
    <investigator>
      <last_name>Javier Ruiz Martinez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Newcastle University</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>Tyne And Wear</state>
        <zip>NE45PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Foster</last_name>
      <phone>+441912081197</phone>
      <email>victoria.foster@ncl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Nicola Pavese</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imperial College London</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital Oxford and Oxford University</name>
      <address>
        <city>Oxford</city>
        <zip>Oxford, OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamil Razzaque</last_name>
      <phone>+441865223166</phone>
      <email>jamil.razzaque@ouh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Michele Hu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 15, 2020</study_first_submitted>
  <study_first_submitted_qc>July 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2020</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute for Neurodegenerative Disorders</investigator_affiliation>
    <investigator_full_name>Ken Marek, MD</investigator_full_name>
    <investigator_title>Protocol Co- Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Parkinson</keyword>
  <keyword>Bio-markers</keyword>
  <keyword>Neurodegenerative disorder</keyword>
  <keyword>Imaging</keyword>
  <keyword>Prodromal</keyword>
  <keyword>Genetics</keyword>
  <keyword>At Risk</keyword>
  <keyword>Loss of Smell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

